Market Access, Reimagined.

MMA.INC announced an exclusive revenue-share peptide partnership tied to Precision Peptide products for the global martial arts community. The release highlights MMA.INC's participation in the peptide therapeutics and recovery market, with the partnership positioned around U.S.-manufactured, third-party tested products and MMA.INC's global customer base.

• The agreement is framed around a 50/50 revenue-share model.
• The release emphasizes MMA.INC's martial arts audience and connected gym ecosystem.
• Precision Peptide is identified as a CSE-listed peptide company.

The Company announced an exclusive strategic marketing agreement dated May 8, 2026 with Mixed Martial Arts Group Limited, a New South Wales, Australia-based company. The partnership is designed to market and sell the Company's peptide products to MMA's subscriber base and combat sports network.

• The agreement focuses on marketing and selling peptide products to MMA's subscribers.
• MMA is described as a large digitally connected combat sports ecosystem with millions of followers and a broad gym network.
• The release reinforces the Company's focus on peptide formulations and delivery systems.

The Company provided an update on the development of its needle-free BPC-157 transdermal patch. The update positions the patch as a frictionless entry point into the peptide category and part of a broader multi-product transdermal platform under Amino Innovations.

• The BPC-157 patch is described as being in active testing.
• The Company expects to move closer to commercial release subject to satisfactory testing milestones.
• The release notes that the patch would sit alongside the existing oral peptide product line.

The Company announced approximately C$1.3 million in proceeds from the exercise of outstanding warrants. Management described the proceeds as strengthening the balance sheet and supporting continued development and expansion of the Amino Innovations platform.

• Proceeds are intended to support product rollout, delivery technology advancement, and distribution growth.
• The release highlights the Company's focus on improving convenience and accessibility in peptide delivery.
• Management tied the financing to execution across the Company's product and distribution strategy.

The Company announced grants of restricted share units and incentive stock options under its omnibus share incentive plan, along with the issuance of common shares to settle outstanding indebtedness owed to a creditor of the Company.

• The release discloses 600,000 RSUs to certain directors, with vesting dates in 2026 and 2027.
• The Company announced 1,100,000 options exercisable at $0.50 per share for three years.
• The debt settlement involved $125,000 in indebtedness through the issuance of 300,000 common shares.

The Company announced a strategic product marketing agreement with Raw Creation, a UK-headquartered creative agency. Services under the agreement include social media management, creative and video production, editorial and press services, landing pages, social copy, and paid advertising management.

• The initial term runs for six months, from April 20, 2026 to October 20, 2026.
• The release discloses a setup fee and six-month prepaid retainer totaling CAD$85,500 for the initial term.
• The agreement is subject to Canadian Securities Exchange approval.

The Company commented on U.S. Food and Drug Administration actions relating to regulatory clarity around peptide substances. The release frames the development as a step toward a more transparent, science-driven regulatory framework for peptide therapies.

• The Company highlighted the FDA's decision to remove several peptides from Category 2 of bulk drug substances and refer them for further evaluation.
• The release connects regulatory clarity with the Company's focus on quality manufacturing and peptide delivery standards.
• The update includes standard forward-looking information and cautions.

The Company announced agreements with Think Ink Marketing Data and Email Services and Ouimet Consulting Inc. Think Ink is engaged for public relations services, while Ouimet is engaged for management consulting, business development, and financial advisory services.

• The Think Ink agreement focuses on increasing public awareness of the Company and its products, services, and securities.
• The Ouimet agreement has a one-month term from April 21, 2026 to May 21, 2026.
• The Company disclosed a USD$65,000 cash fee for the Ouimet agreement, subject to CSE approval.